AR098523A1 - Anticuerpos dirigidos contra matriptasa y composiciones relacionadas - Google Patents
Anticuerpos dirigidos contra matriptasa y composiciones relacionadasInfo
- Publication number
- AR098523A1 AR098523A1 ARP140104405A ARP140104405A AR098523A1 AR 098523 A1 AR098523 A1 AR 098523A1 AR P140104405 A ARP140104405 A AR P140104405A AR P140104405 A ARP140104405 A AR P140104405A AR 098523 A1 AR098523 A1 AR 098523A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- set forth
- Prior art date
Links
- 108010091175 Matriptase Proteins 0.000 title abstract 4
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 206010025323 Lymphomas Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 108010002164 tyrosine receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Proporciona anticuerpos los cuales se unen al dominio extracelular del receptor transmembrana de tirosina - proteína quinasa Matriptasa. También se proveen moléculas de ácido nucleico que codifican los anticuerpos, vectores de expresión, células huéspedes y métodos para expresar los anticuerpos. Los anticuerpos pueden utilizarse para el tratamiento del cáncer, incluyendo cáncer gástrico, cáncer colorrectal, cáncer de próstata, cáncer mamario, cáncer de ovario, cáncer pulmonar, preferentemente SCLC, cáncer de esófago, cáncer de cabeza y cuello, cáncer pancreático, linfoma preferentemente linfoma no de Hodgkin y cáncer de piel. Reivindicación 1: Un anticuerpo aislado, o una porción de unión al antígeno del mismo, el cual: (a) se une a un epítopo en la región del tallo de Matriptasa el cual es reconocido por un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 1 y una región variable de cadena ligera que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 2, o (b) compite por la unión a la región del tallo de Matriptasa con un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 1, y una región variable de cadena ligera que comprende la secuencia de aminoácidos expuesta en SEC ID Nº 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908371P | 2013-11-25 | 2013-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098523A1 true AR098523A1 (es) | 2016-06-01 |
Family
ID=52000873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104405A AR098523A1 (es) | 2013-11-25 | 2014-11-25 | Anticuerpos dirigidos contra matriptasa y composiciones relacionadas |
Country Status (14)
Country | Link |
---|---|
US (1) | US9932411B2 (es) |
EP (1) | EP3074423A1 (es) |
JP (1) | JP2016538852A (es) |
KR (1) | KR20160079818A (es) |
CN (1) | CN105849127A (es) |
AR (1) | AR098523A1 (es) |
AU (1) | AU2014351565A1 (es) |
BR (1) | BR112016011435A2 (es) |
CA (1) | CA2929402A1 (es) |
EA (1) | EA201690806A1 (es) |
IL (1) | IL245551A0 (es) |
MX (1) | MX2016006486A (es) |
TW (1) | TW201605905A (es) |
WO (1) | WO2015075477A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
AR098523A1 (es) | 2013-11-25 | 2016-06-01 | Oxford Biotherapeutics Ltd | Anticuerpos dirigidos contra matriptasa y composiciones relacionadas |
JP7145374B2 (ja) * | 2016-03-18 | 2022-10-03 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化 |
TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
US7022821B1 (en) | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
EP1161266A4 (en) | 1999-03-12 | 2007-09-19 | Univ Georgetown | MATRIPTASE, SERINE PROTEASE, AND USE THEREOF |
US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
CA2388450C (en) | 1999-10-20 | 2013-02-12 | The Board Of Trustees Of The University Of Arkansas | Tadg-15: an extracellular serine protease overexpressed in carcinomas |
US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
AU2001233262A1 (en) | 2000-02-03 | 2001-08-14 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
JP2004535166A (ja) | 2001-03-22 | 2004-11-25 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法 |
CA2442089A1 (en) | 2001-03-27 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
KR20040080940A (ko) | 2001-05-14 | 2004-09-20 | 덴드레온 코포레이션 | 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
US20030170245A1 (en) * | 2002-03-05 | 2003-09-11 | Dickson Robert B. | Activation of matriptase and diagnostic and therapeutic methods based thereon |
US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
ATE504602T1 (de) * | 2004-12-20 | 2011-04-15 | Amgen Fremont Inc | Für humane matriptase spezifische bindungsproteine |
WO2006090389A2 (en) | 2005-02-24 | 2006-08-31 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
EP2185933B1 (en) | 2007-08-07 | 2015-10-07 | Oxford Biotherapeutics Ltd. | Matriptase protein and uses thereof |
DK2285408T3 (en) * | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
CA2818237C (en) | 2009-11-18 | 2021-05-18 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
US8205227B1 (en) | 2010-02-06 | 2012-06-19 | Frontier Communications Corporation | Management and delivery of audiovisual content items that correspond to scheduled programs |
KR20130091132A (ko) * | 2012-02-07 | 2013-08-16 | 한국생명공학연구원 | 메트립타아제-특이적인 인간 항체 및 그의 용도 |
AR098523A1 (es) | 2013-11-25 | 2016-06-01 | Oxford Biotherapeutics Ltd | Anticuerpos dirigidos contra matriptasa y composiciones relacionadas |
-
2014
- 2014-11-25 AR ARP140104405A patent/AR098523A1/es unknown
- 2014-11-25 EP EP14805644.3A patent/EP3074423A1/en not_active Withdrawn
- 2014-11-25 MX MX2016006486A patent/MX2016006486A/es unknown
- 2014-11-25 EA EA201690806A patent/EA201690806A1/ru unknown
- 2014-11-25 WO PCT/GB2014/053470 patent/WO2015075477A1/en active Application Filing
- 2014-11-25 AU AU2014351565A patent/AU2014351565A1/en not_active Abandoned
- 2014-11-25 CN CN201480070410.1A patent/CN105849127A/zh active Pending
- 2014-11-25 JP JP2016532094A patent/JP2016538852A/ja active Pending
- 2014-11-25 US US15/037,929 patent/US9932411B2/en not_active Expired - Fee Related
- 2014-11-25 TW TW103140877A patent/TW201605905A/zh unknown
- 2014-11-25 KR KR1020167013234A patent/KR20160079818A/ko not_active Application Discontinuation
- 2014-11-25 CA CA2929402A patent/CA2929402A1/en not_active Abandoned
- 2014-11-25 BR BR112016011435A patent/BR112016011435A2/pt not_active Application Discontinuation
-
2016
- 2016-05-09 IL IL245551A patent/IL245551A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016538852A (ja) | 2016-12-15 |
TW201605905A (zh) | 2016-02-16 |
WO2015075477A1 (en) | 2015-05-28 |
BR112016011435A2 (pt) | 2017-09-26 |
KR20160079818A (ko) | 2016-07-06 |
MX2016006486A (es) | 2016-08-05 |
CN105849127A (zh) | 2016-08-10 |
US20160289338A1 (en) | 2016-10-06 |
IL245551A0 (en) | 2016-06-30 |
AU2014351565A1 (en) | 2016-06-09 |
EP3074423A1 (en) | 2016-10-05 |
US9932411B2 (en) | 2018-04-03 |
EA201690806A1 (ru) | 2016-09-30 |
CA2929402A1 (en) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
PE20171383A1 (es) | Receptores de antigeno quimericos anti-dll3 y metodos de uso | |
CY1123609T1 (el) | Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων | |
EA202091566A1 (ru) | Содержащая нуклеиновую кислоту липидная наночастица и ее применение | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
JOP20170028B1 (ar) | تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية | |
AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
AR098523A1 (es) | Anticuerpos dirigidos contra matriptasa y composiciones relacionadas | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
CO2018000882A2 (es) | Constructos de anticuerpo para flt3 y cd3 | |
CO2017006651A2 (es) | Anticuerpos anti-c5 | |
CR20180065A (es) | Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3 | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
EA201890866A1 (ru) | Связывающие молекулы, которые ингибируют рост рака | |
AR095611A1 (es) | Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1) | |
CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
PE20200757A1 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
AR097102A1 (es) | Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco | |
CL2011001994A1 (es) | Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo. | |
CL2013001645A1 (es) | Secuencia de acido nucleico aislada que codifica un receptor de antigeno quimerico, el cual comprende un dominio de union a antigeno, un dominio transmembrana, una region de señalizacion coestimulatoria y un dominio de señalizacion cd3 zeta; dicho receptor; celula; vector; y su uso para tratar una enfermedad relacionada con la expresion elevada de un antigeno tumoral. | |
AR088693A1 (es) | Anticuerpos especificos para trop-2 y sus usos | |
EA201492101A1 (ru) | Антитела против fcrn | |
MY175708A (en) | Dna antibody constructs and method of using same | |
MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |